VJHemOnc is committed to improving our service to you

ESH AL 2020 | Targeting T-cell malignancies with CRISPR/Cas9 gene edited universal CAR-T

VJHemOnc is committed to improving our service to you

John DiPersio

John DiPersio, MD, PhD, Washington University School of Medicine, Washington, WA, outlines the role of cellular therapies, particularly CRISPR/Cas9 gene-edited universal CAR T-cells, for the treatment of T-cell malignancies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter